The five-year relative survival rate for stage 4 (distant/metastatic) prostate cancer is about 38%, based on the most recent national cancer registry data from 2015 to 2021. That means roughly 4 in 10 men diagnosed with cancer that has spread beyond the prostate to distant sites are alive five years later. While stage 4 prostate cancer is not considered curable with current treatments, survival times vary enormously depending on where the cancer has spread, how it responds to treatment, and the patient’s age and overall health.
What the Survival Numbers Actually Mean
The 38% five-year survival figure comes from the SEER database, which tracks cancer outcomes across the United States. It’s a “relative” survival rate, meaning it compares men with stage 4 prostate cancer to men of the same age without cancer. This strips out deaths from other causes and isolates the impact of the cancer itself.
About 8% of all prostate cancers are already at the distant (metastatic) stage when first diagnosed. For these men, the National Cancer Institute estimates median survival in the range of 1 to 3 years with standard approaches, though newer combination therapies are pushing that number significantly higher for many patients. At 10 years after diagnosis, roughly 15% to 22% of men with distant-stage prostate cancer are still alive, depending on age at diagnosis.
How Age Affects Survival
Age at diagnosis has a meaningful impact on outcomes, though not always in the direction you might expect. CDC data covering more than 100,000 men with distant-stage prostate cancer shows that the best 10-year survival belongs to men diagnosed between ages 55 and 64, where about 21% to 22% reach the 10-year mark. Men diagnosed before age 55 actually fare slightly worse at 10 years (around 19%), possibly because younger-onset metastatic disease tends to be more aggressive.
The sharpest drop-off happens after age 75. Men diagnosed at 75 to 79 have a 10-year survival of about 18.5%, and those diagnosed at 80 or older drop to roughly 15%. The one-year survival rate also tells this story: about 84% of men under 65 are alive one year after a distant-stage diagnosis, compared to 63% of men over 80. Older men are less likely to tolerate intensive treatments and more likely to have other health conditions that limit their options.
Where the Cancer Spreads Matters
Stage 4 prostate cancer most commonly spreads to lymph nodes and bones. These sites carry a relatively more favorable prognosis compared to spread to internal organs. When cancer reaches the liver or brain, outcomes are significantly worse.
A study tracking patients by their first site of metastasis found striking differences over roughly four years of follow-up. Men whose cancer first spread to the lungs had a 55% survival rate at 50 months. Those with brain metastases dropped to 15%. And men with liver metastases had only a 2% survival rate at the same time point. These differences are large enough that knowing where the cancer has spread is one of the most important pieces of information for estimating prognosis.
Hormone-Sensitive vs. Castration-Resistant Disease
Stage 4 prostate cancer generally passes through two phases, and which phase you’re in dramatically affects life expectancy. Initially, the cancer responds to treatments that lower testosterone (hormone therapy). This is called hormone-sensitive disease. Over time, the cancer adapts and begins growing despite very low testosterone levels, becoming what’s known as castration-resistant disease. This transition marks a turning point.
For men with metastatic hormone-sensitive disease, modern combination treatments have pushed median survival past five years in clinical trials. In one major trial, men receiving a three-drug combination had a median survival exceeding 4.4 years, with the most effective regimen pushing the median so high it hadn’t been reached by the time the study reported results. Men with a lower volume of disease who had previously received local treatment showed the longest survival: a median of about 92 months (nearly 8 years). Men with high-volume disease diagnosed at the same time as the primary cancer had a median closer to 43 months (about 3.5 years).
Once the cancer becomes castration-resistant, the picture changes. Real-world data from Medicare patients shows a median survival of about 26 months from the time castration-resistant disease is diagnosed. More than one in five men in this population did not receive any life-prolonging therapy at all, and fewer than half went on to a second line of treatment, which partly explains the shorter survival in real-world settings compared to clinical trials.
How Treatment Combinations Are Changing Outcomes
The biggest recent shift in stage 4 prostate cancer survival has come from using multiple drugs together upfront rather than adding them one at a time as the disease progresses. The standard foundation is hormone therapy to suppress testosterone. Adding a second drug that blocks testosterone signaling through a different pathway, or adding chemotherapy, has become routine. Now, combining all three (sometimes called “triplet therapy”) is showing the strongest results for men who are healthy enough to tolerate it.
In the ARASENS trial, adding a second hormone-blocking agent to the combination of standard hormone therapy plus chemotherapy reduced the risk of death by 32.5%. The control group had a median survival of about 49 months, while the triplet group’s median hadn’t been reached at the time of analysis, meaning more than half were still alive. The PEACE-1 trial found similar results: the control group survived a median of about 53 months, while the triplet group again exceeded that with a 25% reduction in death risk. These benefits were especially pronounced in men with high-volume disease, the group that historically had the worst prognosis.
For men whose cancer has become castration-resistant and progressed through standard options, a targeted radioactive therapy that homes in on a protein found on prostate cancer cells has shown benefit. In a landmark trial published in the New England Journal of Medicine, this therapy extended median overall survival from 11.3 months to 15.3 months, a 4-month gain with a 38% reduction in the risk of death. It’s typically reserved for later in the treatment sequence after other options have been tried.
The Volume and Timing of Metastasis
Two men can both have stage 4 prostate cancer and face very different timelines. One of the clearest dividing lines is the volume of disease (how many metastatic sites there are) and whether the cancer was already metastatic at diagnosis or spread later after initial treatment.
Men who were first treated for localized prostate cancer and later developed a small number of metastases (low-volume, metachronous disease) have the best outcomes. Their median survival reaches about 92 months, or nearly 8 years. On the other end of the spectrum, men diagnosed with widespread metastatic disease from the start (high-volume, synchronous disease) have a median survival closer to 43 months. This gap of nearly 4.5 years between the best and worst prognostic groups within stage 4 shows why a single survival statistic can be misleading.
Quality of Life and Palliative Support
Because stage 4 prostate cancer involves ongoing treatment that can span years, quality of life becomes a central concern alongside survival. Hormone therapy causes fatigue, hot flashes, bone thinning, and mood changes. Chemotherapy adds its own side effects. Bone metastases frequently cause pain and raise the risk of fractures.
Early involvement of palliative care, which focuses on symptom management and does not mean stopping cancer treatment, has been linked to improved quality of life and even longer survival in studies of other advanced cancers. For men with end-stage disease, earlier enrollment in hospice has been associated with less time spent in hospitals and clinics. In one study of prostate cancer patients, the median time in hospice was only 27 days, suggesting many men are referred later than would be ideal for maximizing comfort.